Development and manufacture of finished pharmaceutical products and pharmaceutical substances.
In 2016, the cluster enterprises produced 149 finished pharmaceutical products and more than 50 tons of pharmaceutical substances. 54 products are currently undergoing registration and more than 20 pharmaceutical products (including 8 original products) to treat disorders in such areas as gastroenterology, gynecology, urology, resuscitation, neurology, oncology are under development are at different stages of preclinical and clinical trials.
Finished pharmaceutical products produced by cluster members include the following groups of drugs:
- Systemic antibacterial drugs
- Cardiovascular system
- Central nervous system
- Oncology
- Blood and bloodmaking organs
- Endocrinology
- Respiratory diseases
- Digestive tract (gastroenterology) and metabolism
- Musculoskeletal and connective tissue disorders
- Antineoplastic substances and immunomodulators
- Genitourinary system and reproductive hormones
- Dermatology
A significant part of pharmaceutical drugs produced by the cluster enterprises currently targets the retail sector.
During the period 2012 to 2016 four full-scale GMP plants with an investment volume of 51.72 billion rubles were opened on the cluster land by Niarmedik-Pharma (NIARMEDIK group), Berlin-Pharma (Berlin-Chemie Menarini group), AstraZeneca (AstraZeneca Industries group) and NovoNordisk (NovoNordisk AB). By the end of 2017, two more plants will be opened by Russian companies - AO PHARM-SYNTEZ and OOO Sfera-Farm - to manufacture finished pharmaceutical products, plasma volume expanders, antiseptics and medications used for peritoneal dialysis.
This companies are also engaged in the development and production of finished pharmaceutical products
- OOO Mir-Pharm
- OOO NPF PharmVILAR
- OOO BION
- AO Obninsk Chemical and Pharmaceutical Company
- OOO Medbiofarm .
Special attention will be given to projects focused on the deepening of technological process stages including the manufacture of pharmaceutical substitutes. The largest foreign companies such as NovoNordisk and AstraZeneca will continue to develop their projects to localize production.
Significant opportunities for the cluster development are not only those related to the expansion of existing production facilities and bringing their output to design capacity but also those related to the implementation of new investment projects including OOO Interfarmglass, OOO Novomedika, etc., which will allow the Kaluga pharmaceutical cluster to become a market leader in terms of quantity and volume of products produced on its territory.
